Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Google Secures Pentagon AI Deal for Classified Projects 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
PRINCETON, N.J., Feb. 16, 2016 -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that Al Altomari, President and Chief Executive Officer will present at the 2016 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 23, 2016 at 8:00 AM ET in New York City, NY.
To access the live and archived webcasts of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. The webcast will be archived on Agile Therapeutics website for 60 days following the event.
About Agile
Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. For more information, please visit the company website at www.agiletherapeutics.com.
Contact Mary Coleman 609-683-1880
